3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
3
Stomach Neoplasms
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Melanoma
1
Malignant Solid Tumour
1
Intestinal Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Digestive System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Paclitaxel
10
Radiotherapy
7
Fluorouracil
7
pembrolizumab
6
Carboplatin
6
Oxaliplatin
5
Cisplatin
5
lenvatinib
3
Neoadjuvant Therapy
3
Cetuximab
3
tislelizumab
2
camrelizumab
2
Surgical Procedures, Operative
2
Nivolumab
2
Leucovorin
2
Irinotecan
2
Drug Therapy
2
Docetaxel
2
tremelimumab
1
toripalimab
1
regorafenib
1
osimertinib
1
oblimersen
1
nimotuzumab
1
nedaplatin
1
monalizumab
1
enzalutamide
1
durvalumab
1
aflibercept
1
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Esophageal Squamous Cell Carcinoma
×
Levoleucovorin
×
Clear all
NCT06780111
2026-03-31
MK-3475-06E
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
298 enrolled